Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2023-2029
Due to the COVID-19 pandemic, the global Radioimmunotherapy market size was US$ 1042.83 million in 2022 and is forecast to a readjusted size of US$ 4479 million by 2029 with a CAGR of 17.43% during the forecast period 2023-2029.
The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, and etc. In 2022, the global top five players hold a share approximately 99.25% in terms of revenue.
The United States Radioimmunotherapy market size was US$ 504.62 million in 2022, while China size was US$ 23.72 million. The proportion of the United States was 48.39% in 2022, while China percentage was 2.27%, and it is predicted that China share will reach 1.44% in 2029, trailing a CAGR of 20.26 % through the analysis period. As for the Europe Radioimmunotherapy landscape, Germany is projected to reach US$ 327 million by 2029.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Radioimmunotherapy market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Radioimmunotherapy market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Radioimmunotherapy market. Readers of the report can become informed about current and future trends of the global Radioimmunotherapy market and how they will impact market growth during the forecast period.
By Company
On Market
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
On Pipeline
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Segment by Type
Beta-emitting
Targeted Alpha Therapy
Segment by Application
Non Hodgkin Lymphoma (NHL)
Solid Tumor
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Middle East & Africa
Middle East
Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Radioimmunotherapy in global and regional level.
Chapter 3: Detailed analysis of Radioimmunotherapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 9: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 10: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radioimmunotherapy revenue, gross margin, and Business Strategy, etc.
Chapter 12: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13: Research Findings and Conclusion
- 1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis By Type
- 1.2.1 Global Radioimmunotherapy Market Size Growth Rate By Type: 2018 Vs 2022 Vs 2029
- 1.2.2 Targeted Alpha Therapy
- 1.2.3 Beta-emitting
- 1.3 Market By Application
- 1.3.1 Global Radioimmunotherapy Market Growth By Application: 2018 Vs 2022 Vs 2029
- 1.3.2 Non Hodgkin Lymphoma (Nhl)
- 1.3.3 Solid Tumor
- 1.4 Assumptions And Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
- 2 Market Perspective
- 2.1 Global Radioimmunotherapy Market Size 2018-2029
- 2.2 Radioimmunotherapy Market Size Across Key Geographies Worldwide: 2018 Vs 2022 Vs 2029
- 2.3 Global Radioimmunotherapy Market Size By Region (2018-2023)
- 2.4 Global Radioimmunotherapy Market Size Forecast By Region (2024-2029)
- 2.5 Global Top 10 Radioimmunotherapy Countries Ranking By Market Size
- 3 Radioimmunotherapy Competition By Company
- 3.1 Global Radioimmunotherapy Revenue By Players
- 3.1.1 Global Radioimmunotherapy Revenue By Players (2018-2023)
- 3.1.2 Global Radioimmunotherapy Market Share By Players (2018-2023)
- 3.2 Global Radioimmunotherapy By Company Type (Tier 1, Tier 2, And Tier 3)
- 3.3 Company Covered: Ranking By Radioimmunotherapy Revenue
- 3.4 Global Radioimmunotherapy Market Concentration Ratio
- 3.4.1 Global Radioimmunotherapy Market Concentration Ratio (Cr5 And Hhi)
- 3.4.2 Global Top 5 Companies By Radioimmunotherapy Revenue In 2022
- 3.5 Global Key Players Of Radioimmunotherapy Head Office And Area Served
- 3.6 Global Key Players Of Radioimmunotherapy, Product And Application
- 3.7 Global Key Players Of Radioimmunotherapy, Date Of Enter Into This Industry
- 3.8 Mergers & Acquisitions, Expansion Plans
- 4 Global Radioimmunotherapy Breakdown Data By Type
- 4.1 Global Radioimmunotherapy Historic Market Size By Type (2018-2023)
- 4.2 Global Radioimmunotherapy Forecasted Market Size By Type (2024-2029)
- 5 Global Radioimmunotherapy Breakdown Data By Application
- 5.1 Global Radioimmunotherapy Historic Market Size By Application (2018-2023)
- 5.2 Global Radioimmunotherapy Forecasted Market Size By Application (2024-2029)
- 6 North America
- 6.1 North America Radioimmunotherapy Revenue By Company (2021-2023)
- 6.2 North America Radioimmunotherapy Revenue By Type (2018-2029)
- 6.3 North America Radioimmunotherapy Revenue By Application (2018-2029)
- 6.4 North America Radioimmunotherapy Revenue By Country (2018-2029)
- 6.4.1 United States
- 6.4.2 Canada
- 7 Europe
- 7.1 Europe Radioimmunotherapy Revenue By Company (2021-2023)
- 7.2 Europe Radioimmunotherapy Revenue By Type (2018-2029)
- 7.3 Europe Radioimmunotherapy Revenue By Application (2018-2029)
- 7.4 Europe Radioimmunotherapy Revenue By Country (2018-2029)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia
- 8 Asia Pacific
- 8.1 Asia Pacific Radioimmunotherapy Revenue By Company (2021-2023)
- 8.2 Asia Pacific Radioimmunotherapy Revenue By Type (2018-2029)
- 8.3 Asia Pacific Radioimmunotherapy Revenue By Application (2018-2029)
- 8.4 Asia Pacific Radioimmunotherapy Revenue By Region (2018-2029)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 India
- 8.4.5 Southeast Asia
- 9 Latin America
- 9.1 Latin America Radioimmunotherapy Revenue By Company (2021-2023)
- 9.2 Latin America Radioimmunotherapy Revenue By Type (2018-2029)
- 9.3 Latin America Radioimmunotherapy Revenue By Application (2018-2029)
- 9.4 Latin America Radioimmunotherapy Revenue By Country (2018-2029)
- 9.4.1 Mexico
- 9.4.2 Brazil
- 10 Middle East And Africa
- 10.1 Middle East And Africa Radioimmunotherapy Revenue By Company (2021-2023)
- 10.2 Middle East And Africa Radioimmunotherapy Revenue By Type (2018-2029)
- 10.3 Middle East And Africa Radioimmunotherapy Revenue By Application (2018-2029)
- 10.4 Middle East And Africa Radioimmunotherapy Revenue By Country (2018-2029)
- 10.4.1 Middle East
- 10.4.2 Africa
- 11 Company Profiles
- 11.1 Bayer
- 11.1.1 Bayer Company Details
- 11.1.2 Bayer Business Overview
- 11.1.3 Bayer Radioimmunotherapy Products And Services
- 11.1.4 Bayer Revenue In Radioimmunotherapy Business (2018-2023)
- 11.1.5 Bayer Radioimmunotherapy Swot Analysis
- 11.1.6 Bayer Business Strategy
- 11.2 Novartis
- 11.2.1 Novartis Company Details
- 11.2.2 Novartis Business Overview
- 11.2.3 Novartis Radioimmunotherapy Products And Services
- 11.2.4 Novartis Revenue In Radioimmunotherapy Business (2018-2023)
- 11.2.5 Novartis Radioimmunotherapy Swot Analysis
- 11.2.6 Novartis Business Strategy
- 11.3 Lantheus
- 11.3.1 Lantheus Company Details
- 11.3.2 Lantheus Business Overview
- 11.3.3 Lantheus Radioimmunotherapy Products And Services
- 11.3.4 Lantheus Revenue In Radioimmunotherapy Business (2018-2023)
- 11.3.5 Lantheus Radioimmunotherapy Swot Analysis
- 11.3.6 Lantheus Business Strategy
- 11.4 Aurobindo Pharma
- 11.4.1 Aurobindo Pharma Company Details
- 11.4.2 Aurobindo Pharma Business Overview
- 11.4.3 Aurobindo Pharma Radioimmunotherapy Products And Services
- 11.4.4 Aurobindo Pharma Revenue In Radioimmunotherapy Business (2018-2023)
- 11.4.5 Aurobindo Pharma Radioimmunotherapy Swot Analysis
- 11.4.6 Aurobindo Pharma Business Strategy
- 11.5 Mundipharma
- 11.5.1 Mundipharma Company Details
- 11.5.2 Mundipharma Business Overview
- 11.5.3 Mundipharma Radioimmunotherapy Products And Services
- 11.5.4 Mundipharma Revenue In Radioimmunotherapy Business (2018-2023)
- 11.5.5 Mundipharma Business Strategy
- 11.6 China Isotope & Radiation
- 11.6.1 China Isotope & Radiation Company Details
- 11.6.2 China Isotope & Radiation Business Overview
- 11.6.3 China Isotope & Radiation Radioimmunotherapy Products And Services
- 11.6.4 China Isotope & Radiation Revenue In Radioimmunotherapy Business (2018-2023)
- 11.6.5 China Isotope & Radiation Radioimmunotherapy Swot Analysis
- 11.6.6 China Isotope & Radiation Business Strategy
- 11.7 Curium Pharmaceuticals
- 11.7.1 Curium Pharmaceuticals Company Details
- 11.7.2 Curium Pharmaceuticals Business Overview
- 11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products And Services
- 11.7.4 Curium Pharmaceuticals Revenue In Radioimmunotherapy Business (2018-2023)
- 11.7.5 Curium Pharmaceuticals Radioimmunotherapy Swot Analysis
- 11.7.6 Curium Pharmaceuticals Business Strategy
- 11.8 Gilead Sciences
- 11.8.1 Gilead Sciences Company Details
- 11.8.2 Gilead Sciences Business Overview
- 11.8.3 Gilead Sciences Radioimmunotherapy Products And Services
- 11.8.4 Gilead Sciences Business Strategy
- 11.9 Clarity Pharmaceuticals
- 11.9.1 Clarity Pharmaceuticals Company Details
- 11.9.2 Clarity Pharmaceuticals Business Overview
- 11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products And Services
- 11.9.4 Clarity Pharmaceuticals Radioimmunotherapy Swot Analysis
- 11.9.5 Clarity Pharmaceuticals Business Strategy
- 11.10 Curasight
- 11.10.1 Curasight Company Details
- 11.10.2 Curasight Business Overview
- 11.10.3 Curasight Radioimmunotherapy Products And Services
- 11.10.4 Curasight Radioimmunotherapy Swot Analysis
- 11.10.5 Curasight Business Strategy
- 11.11 Nordic Nanovector
- 11.11.1 Nordic Nanovector Company Details
- 11.11.2 Nordic Nanovector Business Overview
- 11.11.3 Nordic Nanovector Radioimmunotherapy Products And Services
- 11.11.4 Nordic Nanovector Radioimmunotherapy Swot Analysis
- 11.11.5 Nordic Nanovector Business Strategy
- 11.12 Philogen
- 11.12.1 Philogen Company Details
- 11.12.2 Philogen Business Overview
- 11.12.3 Philogen Radioimmunotherapy Products And Services
- 11.12.4 Philogen Radioimmunotherapy Swot Analysis
- 11.12.5 Philogen Business Strategy
- 11.13 Radiomedix
- 11.13.1 Radiomedix Company Details
- 11.13.2 Radiomedix Business Overview
- 11.13.3 Radiomedix Radioimmunotherapy Products And Services
- 11.13.4 Radiomedix Business Strategy
- 11.14 Telix Pharmaceuticals
- 11.14.1 Telix Pharmaceuticals Company Details
- 11.14.2 Telix Pharmaceuticals Business Overview
- 11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products And Services
- 11.14.4 Telix Pharmaceuticals Radioimmunotherapy Swot Analysis
- 11.14.5 Telix Pharmaceuticals Business Strategy
- 11.15 Orano Med
- 11.15.1 Orano Med Company Details
- 11.15.2 Orano Med Business Overview
- 11.15.3 Orano Med Radioimmunotherapy Products And Services
- 11.15.4 Orano Med Radioimmunotherapy Swot Analysis
- 11.15.5 Orano Med Business Strategy
- 11.16 Actinium Pharmaceuticals
- 11.16.1 Actinium Pharmaceuticals Company Details
- 11.16.2 Actinium Pharmaceuticals Business Overview
- 11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products And Services
- 11.16.4 Actinium Pharmaceuticals Radioimmunotherapy Swot Analysis
- 11.16.5 Actinium Pharmaceuticals Business Strategy
- 11.17 Y-mabs Therapeutics
- 11.17.1 Y-mabs Therapeutics Company Details
- 11.17.2 Y-mabs Therapeutics Business Overview
- 11.17.3 Y-mabs Therapeutics Radioimmunotherapy Products And Services
- 11.17.4 Y-mabs Therapeutics Business Strategy
- 11.18 Fusion Pharmaceuticals
- 11.18.1 Fusion Pharmaceuticals Company Details
- 11.18.2 Fusion Pharmaceuticals Business Overview
- 11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products And Services
- 11.18.4 Fusion Pharmaceuticals Business Strategy
- 12 Radioimmunotherapy Market Dynamics
- 12.1 Radioimmunotherapy Industry Trends
- 12.2 Radioimmunotherapy Market Drivers
- 12.3 Radioimmunotherapy Market Challenges
- 12.4 Radioimmunotherapy Market Restraints
- 13 Research Findings And Conclusion
- 14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.2 Data Source
- 14.2 Author Details
- 14.3 Disclaimer
- List Of Tables
- Table 1. Global Radioimmunotherapy Market Size Growth Rate (Cagr) By Type (Us$ Million): 2018 Vs 2022 Vs 2029
- Table 2. Key Players Of Ibritumomab
- Table 3. Key Players Of Apamistamab
- Table 4. Key Players Of Lilotomab
- Table 5. Key Players Of Omburtamab
- Table 6. Global Radioimmunotherapy Market Size Growth Rate (Cagr) By Application (Us$ Million): 2018 Vs 2022 Vs 2029
- Table 7. Global Radioimmunotherapy Market Size (Us$ Million) Growth Rate (Cagr) By Region: 2018 Vs 2022 Vs 2029
- Table 8. Global Radioimmunotherapy Revenue By Region (2018-2023) & (Us$ Million)
- Table 9. Global Radioimmunotherapy Revenue Forecast By Region (2024-2029) & (Us$ Million)
- Table 10. Global Radioimmunotherapy Market Size Of Top 10 Countries, 2018 Vs 2022 Vs 2029, (Us$ Million)
- Table 11. Global Radioimmunotherapy Revenue By Players (2018-2023) & (Us$ Million)
- Table 12. Global Radioimmunotherapy Market Share By Players (2018-2023)
- Table 13. Global Top Radioimmunotherapy Players By Company Type (Tier 1, Tier 2, And Tier 3) & (Based On The Revenue In Radioimmunotherapy As Of 2022)
- Table 14. Ranking Of Global Top Radioimmunotherapy Companies By Revenue (Us$ Million) In 2022
- Table 15. Global 5 Largest Players Market Share By Radioimmunotherapy Revenue (Cr5 And Hhi) & (2018-2023)
- Table 16. Global Key Players Of Radioimmunotherapy, Headquarters And Area Served
- Table 17. Global Key Players Of Radioimmunotherapy, Product And Application
- Table 18. Global Key Players Of Radioimmunotherapy, Date Of Enter Into This Industry
- Table 19. Mergers & Acquisitions, Expansion Plans
- Table 20. Global Radioimmunotherapy Market Size By Type (2018-2023) & (Us$ Million)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook